Zobrazeno 1 - 10
of 61
pro vyhledávání: '"Hema N, Viswanathan"'
Autor:
David W. Dodick, Anand S. Shewale, Richard B. Lipton, Seth J. Baum, Steven C. Marcus, Stephen D. Silberstein, Jelena M. Pavlovic, Nathan L. Bennett, William B. Young, Hema N. Viswanathan, Jalpa A. Doshi, Howard Weintraub
Publikováno v:
Journal of Primary Care & Community Health, Vol 11 (2020)
Introduction: Triptans, the most commonly prescribed acute treatments for migraine attacks are, per FDA labeling, contraindicated in cardiovascular (CV) disease patients and have warnings and precautions for those with CV risk factors. Methods: Heada
Externí odkaz:
https://doaj.org/article/415cffcf5f8d46a9abb0cffd6b3b36ef
Autor:
Peter D. R. Higgins, Gale Harding, Nancy K. Leidy, Kendra DeBusk, Donald L. Patrick, Hema N. Viswanathan, Kristina Fitzgerald, Sarah M. Donelson, Marcoli Cyrille, Brian G. Ortmeier, Hilary Wilson, Dennis A. Revicki, Gary Globe
Publikováno v:
Journal of Patient-Reported Outcomes, Vol 2, Iss 1, Pp 1-10 (2018)
Abstract Background The clinical course of Crohn’s disease (CD) and the effect of its treatment are monitored through patient-reported signs and symptoms (S&S), and endoscopic evidence of inflammation. The Crohn’s Disease Patient-reported Outcome
Externí odkaz:
https://doaj.org/article/7eb31ad3a3f444e29c26c8e50232e7d3
Autor:
Richard B. Lipton, Pranav Gandhi, Jonathan Stokes, Mary Lynn Cala, Christopher J. Evans, Naomi Knoble, Heather L. Gelhorn, Dennis Revicki, Hema N. Viswanathan, David W. Dodick
Publikováno v:
Headache: The Journal of Head and Face Pain. 62:89-105
To evaluate the content validity and psychometric properties of the Activity Impairment in Migraine Diary (AIM-D).Measuring treatment effects on migraine impairment requires a psychometrically sound patient-reported outcome (PRO) measure developed co
Autor:
Robert Cowan, Jelena M. Pavlovic, Hema N. Viswanathan, Firas Dabbous, Riya Pulicharam, Justin S. Yu, Stephen D. Silberstein, Richard B. Lipton, Michael L. Reed
Publikováno v:
Headache
Objective To evaluate the sensitivity and specificity of the 6‐item Identify Chronic Migraine screener (ID‐CM[6]), designed to improve the detection of chronic migraine (CM). Background CM is often undertreated and underdiagnosed. Survey‐based
Autor:
Jessica Ailani, David W. Dodick, Joel M Trugman, Sihui Zhao, Sung Yun Yu, Anand R. Shewale, Richard B. Lipton, Rashmi B. Halker Singh, Hema N. Viswanathan
Publikováno v:
Headache
Objective To evaluate the efficacy of ubrogepant on patient‐reported functional disability, satisfaction with study medication, and global impression of change. Background Ubrogepant is a small‐molecule, oral calcitonin gene‐related peptide rec
Autor:
Jalpa A. Doshi, William B. Young, Steven C. Marcus, Anand R. Shewale, Richard B. Lipton, Stephen D. Silberstein, Hema N. Viswanathan
Publikováno v:
Cephalalgia
Background Triptans are the most commonly prescribed acute treatments for migraine; however, not all triptan users experience adequate response. Information on real-world resource use and costs associated with triptan insufficient response are limite
Autor:
Hema N. Viswanathan, David W. Dodick, Jalpa A. Doshi, Richard B. Lipton, Steven C. Marcus, Anand R. Shewale
Publikováno v:
Cephalalgia
BackgroundTriptans are the most commonly used acute treatment for migraine. This study evaluated real-world treatment patterns following an initial triptan prescription to understand refill rates and use of non-triptan medications for the acute treat
Autor:
Howard Weintraub, Richard B. Lipton, Nathan L. Bennett, Anand S. Shewale, William B. Young, Hema N. Viswanathan, Jelena M. Pavlovic, Steven C. Marcus, Jalpa A. Doshi, David W. Dodick, Seth J. Baum, Stephen D. Silberstein
Publikováno v:
Journal of Primary Care & Community Health
Journal of Primary Care & Community Health, Vol 11 (2020)
Journal of Primary Care & Community Health, Vol 11 (2020)
Introduction: Triptans, the most commonly prescribed acute treatments for migraine attacks are, per FDA labeling, contraindicated in cardiovascular (CV) disease patients and have warnings and precautions for those with CV risk factors. Methods: Heada
Autor:
Sarah Donelson, Wen Hung Chen, Kristina Fitzgerald, Nancy Kline Leidy, Gale Harding, Dennis A. Revicki, Brian G. Ortmeier, Kendra DeBusk, Peter D.R. Higgins, Hema N. Viswanathan, Donald L. Patrick
Publikováno v:
Journal of Patient-Reported Outcomes, Vol 2, Iss 1, Pp 1-9 (2018)
Journal of Patient-Reported Outcomes
Journal of Patient-Reported Outcomes
Background The clinical course of ulcerative colitis (UC) and the effects of treatment are assessed through patient-reported signs and symptoms (S&S), and endoscopic evidence of inflammation. The Ulcerative Colitis Patient-Reported Outcomes Signs and
Developing a preference-based utility scoring algorithm for the Psoriasis Area Severity Index (PASI)
Autor:
Randall H Bender, Katie D. Stewart, Katherine Kim, Alex Mutebi, John Brazier, Alan Menter, Louis S. Matza, Hema N. Viswanathan, Lionel Pinto, Jessica B Jordan, Leon H Kircik
Publikováno v:
Journal of medical economics. 22(9)
Introduction: It is challenging to identify health state utilities associated with psoriasis because generic preference-based measures may not capture the impact of dermatological symptoms....